Biblio

Author Title Type [ Year(Asc)]
Filters: Author is DiPersio, John  [Clear All Filters]
2021
Alotaibi H, Aljurf M, de Latour R, Alfayez M, Bacigalupo A, Fakih REl, Schrezenmeier H, Ahmed SOsman, Gluckman E, Iqbal S, et al. Upfront Alternative Donor Transplant Versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack Fully HLA Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies. on Behalf of the Severe Aplastic Anemia W. Transplant Cell Ther. 2021.
2020
Shea L, Watkins MP, Wan F, Cashen A, Wagner-Johnston N, Jacoby M, Abboud C, DiPersio J, Hurd D, Jaglowski S, et al. A pilot study of lenalidomide maintenance therapy after autologous transplantation in relapsed or refractory classical Hodgkin lymphoma. Biol Blood Marrow Transplant. 2020.
2016
Fiala MA, Slade M, Wang S, Park S, DiPersio J, Stockerl-Goldstein K. The impact of diabetes mellitus and other comorbidities on hematopoietic stem cell collection and hematologic recovery post-transplantation. Leuk Lymphoma. 2016:1-3.
Pasquini MC, Le-Rademacher J, Zhu X, Artz A, DiPersio J, Fernandez H, Mineishi S, Kamishohara M, Mehta J, Nakamura Y, et al. Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies. Biol Blood Marrow Transplant. 2016.
Ghobadi A, Choi J, Fiala MA, Fletcher T, Liu J, Eissenberg LG, Abboud C, Cashen A, Vij R, Schroeder MA, et al. Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. Leuk Res. 2016;49:1-6.
Cashen AF, Fletcher T, Ceriotti C, Gao F, Ghobadi A, Vij R, Stockerl-Goldstein K, DiPersio J, Abboud C. Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine (BEAM) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016.